4//SEC Filing
ROBITAILLE GREGORY J 4
Accession 0001104659-21-039210
CIK 0001467652other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 5:23 PM ET
Size
20.0 KB
Accession
0001104659-21-039210
Insider Transaction Report
Form 4
ROBITAILLE GREGORY J
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-03-19−12,500→ 0 totalExercise: $15.00→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-19−14,777→ 0 totalExercise: $9.63→ Common Stock (14,777 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-19−22,756→ 0 totalExercise: $6.05→ Common Stock (22,756 underlying) - Disposition to Issuer
Common Stock
2021-03-19−79,130→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-19−10,416→ 0 totalExercise: $9.32→ Common Stock (10,416 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-19−18,322→ 0 totalExercise: $7.65→ Common Stock (18,322 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-03-19−46,907→ 0 totalExercise: $1.44→ Common Stock (46,907 underlying)
Footnotes (4)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time").
- [F2]At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio) shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement).
- [F3]This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock.
- [F4]At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.
Documents
Issuer
Neos Therapeutics, Inc.
CIK 0001467652
Entity typeother
Related Parties
1- filerCIK 0001238910
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 5:23 PM ET
- Size
- 20.0 KB